Skip to Content

Mylan's Win is Teva's Loss

We're increasing our fair value estimate on the former and decreasing our fair value on the latter, due to Mylan's approval of it generic version of Teva's Copaxone.

Michael Waterhouse Oct 4, 2017

Securities In This Article

Although we have long anticipated a generic Copaxone 40mg approval in the near term,

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

More in Stocks

Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?

With a focus on discretionary spending and margins, here’s what we’ll be watching for in Target’s earnings.

Noah Rohr May 16, 2024

Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains

We plan to raise our fair value estimate of Walmart stock.

Noah Rohr May 16, 2024

After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?

With expenses on the rise but its stock down 25%, here’s what we think of Shopify’s outlook.

Dan Romanoff, CPA May 16, 2024

About the Author

View All Authors

Michael Waterhouse

Sector Strategist

More from Author

Michael Waterhouse is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He covers specialty pharmaceutical and life science and diagnostic companies.

Before joining Morningstar in 2010, Waterhouse was a research biologist for the Centers for Disease Control and Prevention. He was also a volunteer in the Peace Corps.

Waterhouse holds a bachelor’s degree in biology from the University of Georgia. He also holds a master’s degree in business administration from the University of Minnesota, where he participated in the Carlson Funds Enterprise, a student managed investment fund.

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.